Benzinga | Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals

Market Overview

6.900 -0.39 (-5.35%)

Data as of Apr 24, 2018

Prev. Close 7.29
Price Open 6.94
Volume 22,097
Day's Range 6.9 - 7.32
52 Wk Range 1.799996 - 15.779968
50 Day Moving Avg. 6.93
PE Ratio 0
Shares Outstanding 2.31M
Market Cap 15.79M

Trade EVFM stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Evofem Biosciences Reports Launch Of $40M Offering Of Common Stock Paul QuintaroTue, 24 Apr 2018 06:54:00 -0400
30 Stocks Moving In Friday's Mid-Day Session Lisa LevinFri, 23 Mar 2018 13:10:32 -0400
H.C. Wainwright Initiates Coverage On Evofem Biosciences with Buy Rating, Announces $15.00 Price Target Eddie StaleyMon, 19 Mar 2018 07:10:43 -0400
34 Stocks Moving In Wednesday's Mid-Day Session Lisa LevinWed, 21 Feb 2018 13:34:21 -0400
Benzinga Pro's Stocks To Watch Today Jayson DerrickWed, 21 Feb 2018 11:23:26 -0400
Evofem Biosciences Receives Fast Track Designation From the FDA for Amphora for Prevention of Chlamydia Paul QuintaroWed, 21 Feb 2018 07:57:16 -0400
Evofem Biosciences Receives Fast Track Designation for Amphora for Prevention of Chlamydia Eddie StaleyWed, 21 Feb 2018 07:57:02 -0400
Evofem Biosciences Shares Down 5.66%; Stock Initially Popped Tuesday To High Of $12 On News Of Clinical Trial Initiation But Quickly Pared Gains To End The Session Down 4% From Prior Close Hal LindonWed, 24 Jan 2018 16:09:57 -0400
Evofem Biosciences Announces First Patient Enrolled in Phase 2b/3 STI Trial of Amphora and Expects Phase 3 Contraceptive Clinical Trial Data First Quarter 2019 Paul QuintaroTue, 23 Jan 2018 08:39:10 -0400
{{ story.title }} {{ story.author }}{{ story.created }}

Evofem Biosciences Announces Proposed Public Offering of Common Stock PRNewswire6 hours ago
Evofem Biosciences Receives Fast Track Designation for Amphora for Prevention of Chlamydia PRNewswireFeb 21, 2018
Evofem Biosciences to Present at RBC Global Healthcare Conference PRNewswireFeb 16, 2018
Evofem Biosciences Completes Enrollment of Phase 3 Contraceptive Trial of Amphora Ahead of Schedule PRNewswireFeb 15, 2018
Evofem Biosciences Announces First Patient Enrolled in Phase 2b/3 STI Trial of Amphora® and Expects Phase 3 Contraceptive Clinical Trial Data First Quarter 2019 PRNewswireJan 23, 2018
{{ story.title }} {{ story.author }}{{ story.created }}

Evofem readies stock offering Seeking Alpha5 hours ago
Evofem Bio readies $57.5M stock offering Seeking AlphaApr 09, 2018
Premarket analyst action - healthcare Seeking AlphaMar 19, 2018
Your Daily Pharma Scoop: Portola Update, Wave Life Sciences To Collaborate With Takeda, AbbVie Reports Data For Egolix Seeking AlphaFeb 21, 2018
Evofem Bio's Amphora Fast Track'd for prevention of chlamydia in women Seeking AlphaFeb 21, 2018
Your Daily Pharma Scoop: Portola Still Attractive, Johnson & Johnson Reports Q4 Results, Cerus Reports Positive Results Seeking AlphaJan 25, 2018
{{ story.title }} {{ story.author }}{{ story.created }}

Brokerage Center

Compare All Online Brokerages